登录 | 注册    关注公众号  
微信公众号
搜索
 >  Antibody>PD-1 >HGS-S238

Recombinant Monoclonal Anti-PD-1 Antibody, Mouse (2F3)

描述/背景(Background)

Programmed cell death protein 1 (PDCD1) is an immune-inhibitory receptor expressed in activated T cells; it is involved in the regulation of T-cell functions, including those of effector CD8+ T cells. In addition, this protein can also promote the differentiation of CD4+ T cells into T regulatory cells. PDCD1 is expressed in many types of tumors including melanomas, and has demonstrated to play a role in anti-tumor immunity. Moreover, this protein has been shown to be involved in safeguarding against autoimmunity, however, it can also contribute to the inhibition of effective anti-tumor and anti-microbial immunity.

种属(Host Species)

Mouse

克隆号(Clone)

2F3

适用方法(Application)

IHC

效价(Property)

1:500

状态(State)

Liquid

阳性对照(Positive Control)

Human Tonsil Tissues

克隆类型(Clonality)

Monoclonal

分子别名(Synonym)

PD1, CD279, PD-1, PDCD1

研究领域(Research Field)

Cancer Drug Targets

抗体来源(Source)

Mouse

同种型(Isotype)

IgG

储存(Storage)

Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.

 

典型数据(Typical Data)

质控样本(Control Sample)

PD-1 CONTROL SAMPLE

Immunohistochemical analysis of paraffin embedded Human tonsil tissue labelled with HGS-S238 at 1/500 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

肿瘤样本(Cancer Sample)

PD-1 CANCER SAMPLE

PD-1 CANCER SAMPLE

Immunohistochemical analysis of paraffin embedded human cancer tissue labelled with HGS-S238 at 1/500 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
PD-1靶点信息
英文全称:Programmed cell death protein 1
中文全称:细胞程序性死亡-1
种类:Homo sapiens
上市药物数量:16详情
临床药物数量:150详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定